ClinicalTrials.gg
RecruitingNCT07351734COPDUpdated Jan 20, 2026

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD

A Phase 2 interventional study of JKN2403 Tablets and Placebo in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
153rd of 289
120 · median 160
Started
2025
with 41 others
Phase 2
33 of 407
13 open now
Primary completion
2026-09
later than 42 of 127 live
Registered
363rd of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 153rd largest by planned enrollment of the 289 interventional ones that give a count, is one of 42 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 42 of the 127 other live ones, and was the 363rd registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

105 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403. The main questions it aims to answer are:

Does drug JKN2403 reduce the incidence of AECOPD or improve the quality of life or alleviate symptoms related to COPD?

Researchers will compare drug JKN2403 to a placebo (a look-alike substance that contains no drug) to see if drug JKN2403 works to treat moderate-to-severe COPD.

Participants will:

Take drug JKN2403 or a placebo every day for 24 weeks Visit the clinic once every four weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ; able and willing to comply with study procedures.
  • Adults with documented diagnosis and medical history consistent with guideline criteria.
  • Relevant exposure history consistent with COPD (e.g., smoking).
  • On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.
  • Protocol-defined exacerbation history, symptom burden, and lung function at screening.

Exclusion criteria

Exclusion Criteria:

  • Current or past asthma, or other respiratory disease that may confound assessment.
  • Clinically significant uncontrolled comorbidities that increase risk or interfere with participation/outcomes.
  • Immunodeficiency/immune dysregulation, active disease requiring systemic , or significant opportunistic infection history.
  • Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined exacerbation.
  • Current/recent (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.
  • Prohibited recent vaccines or therapies, prior relevant biologic/targeted therapy exposure, severe to biologics/IMP, - pregnancy/breastfeeding, or inability to comply (including substance abuse), per investigator judgment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    dose1 of JKN2403 Tablets, once daily orally

    dose1 of JKN2403 Tablets once daily orally, for 24 weeks

    Drug: JKN2403 Tablets

  • Experimental
    dose2 of JKN2403 Tablets once daily orally

    dose2 of JKN2403 Tablets once daily orally, for 24 weeks

    Drug: JKN2403 Tablets

  • Experimental
    dose3 of JKN2403 Tablets once daily

    dose3 of JKN2403 Tablets once daily orally, for 24 weeks

    Drug: JKN2403 Tablets

  • Placebo comparator
    Placebo once daily

    Placebo once daily orally, for 24 weeks

    Drug: Placebo

Interventions

  • DrugJKN2403 Tablets

    JKN2403 Tablets once daily orally, for 24 weeks

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The annualized incidence rate of moderate to severe AECOPD

    Time frame: at 24 months

  2. The duration from the first administration to the first occurrence of moderate to severe AECOPD

    Time frame: at 24 months

Secondary outcomes

  1. trough (pre-bronchodilator) FEV1

    Time frame: at 4, 8, 12 ,16, 20 and 24 weeks

  2. quality of life(SGRQ score)

    Time frame: at 4, 8,12, 16, 20 and 24 weeks

  3. quality of life (CAT score)

    Time frame: at 4, 8,12, 16, 20 and 24 months

  4. The annualized incidence rate of CID

    Time frame: at 24 weeks

  5. The duration from the first administration to the first occurrence of CID

    Time frame: at 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 10 months is below that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2026
First posted
Jan 20, 2026
StartActual
Nov 6, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351734
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Nov 6, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Weijie Guan Professor
Contact
battery203@163.com
020-81566265

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion